Rare genetic disorder of the posterior segment of the eye Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

Regulatory Watchboard

1 event

Apr 2005

Retisert: FDA approved

Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Rare genetic disorder of the posterior segment of the eye.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Retisert

(Fluocinolone)Orphan drug

Bausch & Lomb Pharmaceuticals, Inc.

Corticosteroid [EPC]

12.1 Mechanism of Action Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They in...

Approved Apr 2005FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Rare genetic disorder of the posterior segment of the eye.
Search all trials →

Search clinical trials for Rare genetic disorder of the posterior segment of the eye →

Recent News & Research

No recent news articles indexed yet for Rare genetic disorder of the posterior segment of the eye.
Search PubMed for Rare genetic disorder of the posterior segment of the eye →

Browse all Rare genetic disorder of the posterior segment of the eye news →

Specialist Network

No specialists currently listed for Rare genetic disorder of the posterior segment of the eye.

View all Rare genetic disorder of the posterior segment of the eye specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰